Prostate cancer liver metastasis: Dormancy and resistance to therapy
Authors:
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 71, 2-9
Abstract
No abstract availableKeywords
Funding Information
- National Key R&D Program of China (2018YFA0900900)
- Department of Defense Prostate Cancer Research Program, DOD
- PCRP Prostate Cancer Biorepository Network
- VA Merit Award
This publication has 63 references indexed in Scilit:
- Surface Tethered Epidermal Growth Factor Protects Proliferating and Differentiating Multipotential Stromal Cells from FasL-Induced ApoptosisStem Cells, 2012
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancerCancer and Metastasis Reviews, 2012
- Partial Mesenchymal to Epithelial Reverting Transition in Breast and Prostate Cancer MetastasesCancer Microenvironment, 2011
- The Liver Prometastatic Reaction of Cancer Patients: Implications for Microenvironment-Dependent Colon Cancer Gene RegulationCancer Microenvironment, 2011
- How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicineBritish Journal of Cancer, 2010
- Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transitionMolecular Cancer, 2010
- E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomasClinical & Experimental Metastasis, 2008
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherinBritish Journal of Cancer, 2007